News

The study compared the diuretics torsemide and furosemide that were prescribed to patients with heart failure starting in the hospital setting.

A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with...

Elucid has developed FDA-cleared Plaque Analysis and investigational FFRCT tools designed to enable physicians to diagnose and understand the direct cause of myocardial ischemia, while also identifying coronary plaque that is at highest risk...

Dr. Mehran, who is also a Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes at Icahn Mount Sinai, is the first Mount Sinai cardiologist and the 26th in the U.S. to receive this honor.

Viz.ai will offer Us2.ai’s FDA-cleared and CE Marked echocardiogram viewing and measurement tools with the Viz™ Platform to improve and speed the coordination of care for patients with suspected heart disease, the leading cause of death...

Medtronic announced the results of two clinical studies on the use of the IN.PACT™ Admiral™ drug-coated PTA balloon catheter (DCB). These results were presented in late-breaking clinical trial sessions at VIVA 2022 in Las Vegas. One presented...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final Late-Breaking Clinical Trials session at the VIVA22...

 Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled clinical tools have to be easily available and used.

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of three Late-Breaking Clinical Trials sessions at...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of three Late-Breaking Clinical Trials sessions at...